Clinical Trial Update: Safety and Efficacy of the ONCOlytic VIRus Armed for Local Chemotherapy, TG6002/5-FC, in Recurrent Glioblastoma Patients [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update reports on the safety and efficacy of the ONCOlytic virus TG6002 with its prodrug 5-FC in recurrent glioblastoma, spanning Phase 1 and Pha…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Brain Cancer
• Glioblastoma

Drugs mentioned

• 5-fluorocytosine (5-fluorocytosine)
• TG6002 (oncolytic vaccinia virus TG6002)

Snippet

Sponsor: Assistance Publique - Hôpitaux de Paris | Conditions: Glioblastoma, Brain Cancer | Phase 1, Phase 2 | Status: UNKNOWN